From the University of Liverpool and Callaghan Innovation in New Zealand comes a study that local scientists have been developing; a new kind of chemical approach that will harness the natural ability of complex sugars in the treatment Alzheimer’s disease. The team of scientists produced a new library of sugars called heparan sulphates, which […]
Researchers at Lund University in Sweden headed by Professor Singerup Linse and Erik Helistrand have recently identified a molecular mechanism behind the crucial step in Alzheimer’s that leads to the death of brain cells. The neurological disease is associated, as a general statement, with memory loss and changes in personality. The research at Lund […]
Within the journal Science, University of Pittsburgh Graduate School of Public Health scientists confirm that a study performed on mouse models of Alzheimer’s disease had significantly improved brain function and memory capabilities after being treated with an anti-cancer drug. The cancer drug, known as bexarotene, has previously been studied and used for the treatment cutaneous […]
At Queen Mary University in London, researchers have conducted the largest study of genetic sequencing of human diseases known to date, identifying the genetic basis of six different diseases: autoimmune thyroid disease, celiac disease, Crohn’s disease, psoriasis, multiple sclerosis, and type 1 diabetes. According to the study, though the exact causes of these diseases […]
A study published in the May 2013 online issue of Neurology follows researchers in Minneapolis who performed a study where 1,102 participants, of an averaged an age of 79, were followed for the span of 3.7 years and tested to see if ever they developed dementia. At the start of the study, 109 of the […]
According to Northwestern Medicine Research, new experimental molecules have great promise in targeting enzymes in the brain that prevent memory loss in Alzheimer’s disease. Developed in D. Martin Watterson’s laboratory, the molecules halted memory loss and were able to fix damaged communication between brain cells in mice. Researchers identified and targeted a key enzyme: a […]
Drs. David Holtzman and Mac Diamond of the Washington University School of Medicine recently published research in Neuron that outlined the process of studying mice for potential tau protein tangle treatment avenues. Tau is a toxic component of Alzheimer’s and other neurodegenerative diseases, due to the protein’s tendency to amass in tangles. The aggregates, called […]
Cedars-Sinai scientists published a study in Journal of Clinical Investigation that suggests ACE inhibitors, in the right context and at the right time, can be a good thing. Many people with high blood pressure take ACE inhibitors, medication meant to widen blood vessels by limiting activity of ACE (angiotensin-converting enzyme), a naturally occurring protein. […]
Researchers at Houston Methodist’s Nantz National Alzheimer Center are studying an investigational drug to slow brain cell deterioration in patients with mild to moderate Alzheimer’s disease. T-817MA focuses on preventing brain cell loss and slowing disease progression, where current treatment options like Donepezil, Rivastigmine, and Memantine only treat the symptoms. The scientists want to know […]
A study conducted recently at the Univeraity of California- San Francisco published online in JAMA Internal Medicine. The research was focused in on finding a close link between diabetes and dementia. According to the journal, diabetic patients with low blood sugar may have an increased risk of developing dementia, and patients with dementia or other […]
Researchers at Sanford-Burnham Medical Research Institute have developed the first experimental drug named NitroMemantine that boosts brain synapses lost to Alzheimer’s disease. The medication combines two FDA-approved drugs to stop destructive cascades within the brain, which destroys the connections between neurons and ultimatly leads to memory loss and a decline in cognition. Dr. Stuart A. […]
Researchers at the Michigan Alzheimer’s Disease Center discovered that flavored ECGC, or epigallocatechi-3-gallate, found in green tea could bind to the toxic protein beta-amyloid and prevent its build-up. When ECGC binds to the protein, it is able to change beta-amyloid’s properties. Dr. Mi Hee Lim, lead researcher of the study, found that ECGC bonded to […]
A recent report from researchers at the Massachusetts General Hospital which identifies a protein that aids the immune system in the removal of A-beta protein from the brain, could lead to new treatments of Alzheimer’s disease. According to cocorresponding author of the report, Dr. Joseph Eli Khoury of the Center for Immunology and Inflammatory Diseases […]
Mayo clinic researchers demonstrated within a mouse model that a synthetic peptide carrier works to deliver brain cancer chemotherapy drugs, as well as neurological medications. Neuroscientist Gobinda Sarkar, Ph.D, of the Mayo Clinic and corresponding author of the study discussed that they were able to transport eight different molecules, and much less disruptively through the […]
According to research by the Washington University School of Medicine, published in Science Translational Medicine, a common antidepressant can reduce the production of brain plaques. Brain plaques correlate closely with memory problems and other cognitive impairments caused by Alzheimer’s disease. Stopping plaque buildup is believed to help halt the mental decline of Alzheimer’s patients. Scientists […]
Amino Acids Improve Sleep in Mice with Traumatic Brain Injury A study by Oregon Health and Science University, published in Science Translational Medicine, discovered a way to fix sleep disturbances in mice suffering from traumatic brain injury. These results are important, because people commonly experience long-term and severe sleep and wakefulness issues after suffering concussions, […]
In a recent study, scientists at the Queensland Brain Institute (QBI) at the University of Queensland and Harvard University have found in their research that the length of the mitochondria may be related to Alzheimer’s treatment. Mitochondria are organelles that metabolize energy for the all the cells. The scientists found in cases where there were […]
A new study recently published in the journal Annals of Neurology discussed the identification of what could be the earliest-known biomarker that is associated with the risk of developing Alzheimer’s disease. Results of the study showed that the biomarker was present within Cerebral Spinal Fluid (CSF) for at least a decade before any signs of […]
Perform a web search on “brain scam” and you will find several articles questioning the veracity of claims made with respect to brain fitness or brain exercise programs. Are these programs a scam? One thing is clear, they appear to be rapidly increasing in popularity – all the way from self help books and DVDs […]
A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss. Dr. Paul Newhouse, a professor of psychiatry at Vanderbilt University Medical Center, led a study which showed that six months of nicotine patch treatment among patients who had mild cognitive impairment […]
The Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Drs. Corbin Bachmeier, Daniel Paris, and Michael Mullan at the Roskamp Institute have been working on ways to improve the removal of the Alzheimer amyloid peptide from the brain. Using […]
Dr. Mullan Alzheimer Research Institute helps high school student to be involved in research……… Roskamp Institute aids high school students in genetic research Roskamp aids high school students in genetic research By JENNIFER RICH – firstname.lastname@example.org They look like scientists in their white coats, working in the Roskamp Institute’s lab using microscopes and high-tech research […]
Alzheimer’s disease: Amyloid Plaque (Excerpt from “On The Forefront”) Video shows Dr. Michael Mullan (Dr. Mullan Alzheimer Researcher at the Roskamp Institute) presenting information to audience about Alzheimer’s Disease.Beta Amyloid Presentation By Dr. Michael Mullan (Mullan Alzheimer Researcher)
Dr. Fiona Crawford presentedVideo of Alzheimer Research Institute Headed By Dr. Mullan Presentation on Traumatic Brain Injury a synopsis of her recent study of traumatic brain injury (TBI). Her recently published findings show how TBI can affect the brain’s inflammatory mechanisms, changes in protein levels and cellular pathways, long after the original trauma. Dr. Crawford’s […]
Roskamp Institute Director Dr. Michael Mullan was one of many who represented the biotech industry at the Biotechnology Legislative Caucus yesterday to request more state funding in helping the industry thrive in the state. This is important to Florida this would help the state diversify its economy more, and many organizations within the state have […]
As reported in today’s Bradenton Herald, the Roskamp Institute is searching for clinical trial participants for two potential Alzheimer’s disease treatments. Bapineuzumab and ELND005 are being tested; both hope to successfully remove plaque from the brain which helps cause the condition. For more information please visit the Roskamp Institute Clinical Trial Division web page.
The Sarasota Herald-Tribune reports today in an article titled “In quest to unravel Alzheimer’s, drug may soon be tested locally” that The Roskamp Institute is planning to conduct a clinical trial of a potential Alzheimer’s disease treatment this summer. It will occur in the Sarasota, Florida area, where the Institute is located.
The Roskamp Institute announced today that it will host a neuroscience doctorate research program as part of The Open University’s — of Milton Keynes, England — Affiliated Research Centre. This is the first program of this kind in Florida and will help students prepare better for researching Alzheimer’s disease and related disorders as they work […]
The Roskamp Institute announced on December 14, 2007 that an independent Tokyo Medical University study validates its ongoing research into the Alzheimer’s Disease drug Nilvadipine which is in testing. The International Journal of Geriatric Psychiatry details the results of study that suggests that Nilvadipine can prevent in people with memory problems the onset of Alzheimer’s. […]
On December 6, 2007 the Economic Development Council (EDC) of the Manatee Chamber of Commerce presented the Roskamp Institute with the 2007 Innovation and Technology Award. The EDC honored the Institute since it has made meaningful contributions to scientific research as it studies neuropsychiatric and neurodegenerative conditions, especially Alzheimer’s Disease. The Roskamp Institute and EDC […]
The Roskamp Institute is currently determining whether beta-amyloid, a protein, is useful in the screening of individuals who are at risk of developing Alzheimer’s Disease and monitoring how current sufferers are responding to treatments. Scientists at the Institute have published their scientific findings that indicate that beta-amyloid could serve as an important biomarker for the […]
The recent findings showing that certain anti-hypertensive (drugs which lower hypertension) drugs may be helpful in Alzheimer’s disease, is consistent with the work of the Roskamp Institute. The Roskamp Institute has been conducting pioneering research in this area for several years and is currently conducting a clinical trial in Europe to test whether a […]
The Traumatic Brain Injury Program at the Roskamp Institute Among the soldiers who survive conflicts in Iraq and Afghanistan, the traumatic brain injuries account for a larger proportion of their casualties than in any other US war in recent history. According to the Joint Theater Trauma Registry, established by the U.S. Army Institute of Surgical […]
Melanie Marquez, a reporter at the Bradenton Herald, reports that Senator Bill Nelson of Florida visited Roskamp Institute yesterday. The institute was recently funded $1.5 million by the US Department of Defense to conduct research in Traumatic Brain Injury (TBI). Roskamp Institute research work may help soldiers like those in Iraq who suffer injury due […]
Jeremy Willis of the Herald Tribune reports that U.S. Senator Bill Nelson is touring Florida during his congressional August vacation, and Melanie Marquez of the Bradenton Times explains that Nelson learned during his visit to the Roskamp Institute yesterday that it is conducting federally funded research that could help soldiers with traumatic brain injuries. The […]
Reuters reports that US health officials have required Novartis AG to correct misleading information in its advertising and marketing campaign for its Alzheimer’s drug Exelon. The questioned information was printed on file cards distributed to health care professionals.
One of the biggest fears that Alzheimer’s caregivers have are that those to whom they attend to will wander off — potentially finding themselves lost and in danger. Associated Press medical writer Lauran Neergaard talks about a few options in her article today titled “Helping find lost Alzheimer’s patients.” She discusses cheap devices that cost […]
The Associated Press reports in an article about Alzheimer’s caregiving today that “Offering simple training to people struggling to care for loved ones with Alzheimer’s disease not only eases their burden — it even can keep patients out of nursing homes for an extra 1 1/2 years.” However, many people who care for loved ones […]
BBC News reports Barbara Pointon, who was the subject of a British TV documentary since he lost her husband to Alzheimer’s Disease, is going to serve as a dementia adviser to the British government. The last 11 years of her husband’s life were documented as he suffered from the condition. She’ll likely serve as a […]
The news aggregating site Topix has an Alzheimer’s Disease discussion forum in which people discuss various news item related to the condition. Check it out.
Today the Roskamp Institute announced that one of its studies, led by Dr. Robert Farese, identifies a mechanism behind obesity and Type 2 Diabetes. Although the research center typically focuses on cognitive conditions like Down Syndrome, it is believed that diabetics are more likely to suffer from Alzheimer’s Disease.
The Associated Press reports that French President Nicholas Sarkozy has declared his commitment to curing Alzhemier’s Disease as he visited a retirement home and geriatric hospital wing in Dax, France. Before winning this year’s election, he in May asserted the importance of “doctors with the means to find the solution. The objective must be the […]
According to Reuters, Dr. Milan Fiala of the Greater Los Angeles Veteran’s Affairs Medical Center found in a laboratory study that a chemical found in the common curry spice turmeric can help boost the immune system of Alzheimer’s Disease patients. Hopefully, these findings are accurate since tumeric is a cheap, readily available substance.
In an upbeat article from February about the prospects of those who suffer from Down Syndrome and Alzheimer’s Disease, Stephanie Hayes of The St. Petersburg Times explains how the Roskamp Institute‘s trial of a new treatment for Alzheimer’s could further improve the life of those who have the disease.
Neuropsychology — which examines how human behavior, cognition, and emotion relate to the brain — is one of many fields that the Roskamp Institute uses to address health issues related to memory and Alzeheimer’s. For more information about it, read the journal titled Neuropsychology.
John Hopkins University found that Alzheimer’s cases may quadruple by 2050 in a study funded by Elan Pharmaceuticals and Wyeth Pharmaceuticals.
Alzheimer’s is a tough disease to endure or see a love one endure. Find support in the many Alzheimer’s support groups hosted on Yahoo!.
Last year on World Alzheimer’s Day — September 21, 2006 — the Roskamp Institute helped celebrate a day by starting a clinical trial, and for the first time the trial is on a product of Roskamp’s own work. Hopefully, this study will yield positive results for Alzheimer’s research.
The Roskamp Institute is helping with trials for the Alzheimer’s drug Nilvadipine to get it approved for use in the United States, and the Herald Tribune in Florida reports that the human trials are going well. If all goes well with Nilvadipine, we’re one step closer to making life much better for those who suffer […]
Following is a video of a local television show on the Roskamp Institute’s new alzheimer’s treatment. roskamp roskamp institute alzheimers michael mullan
The story we featured a few weeks ago has been picked up by the Orlando Sentinel. You can read the story here. roskamp roskamp institute alzheimers michael mullan
There was a good story a few week’s back that features our Executive Director, Michael Mullan. Here are the key quotes: Because people with Down’s syndrome have an extra copy of that chromosome, they produce more of the protein. A part of that protein, beta-amyloid, builds up as plaque on the brain. “We may still […]
We have just put out a press release announcing the Roskamp Institute’s participation in a multiple sclerosis study. Here’s a quote from Michael Mullan: “We are looking for volunteers to participate in this pharmaceutical sponsored research study to assess the effectiveness and safety of the investigational drug fingolimod, used to treat patients with relapsing-remitting MS,” […]
One of the key aspects of our research at the Roskamp Institute is clinical trials. Without qualified volunteers, our work is impossible. We are currently recruiting volunteers for our clinical trials, which are run by our Scientific Director, Michael Mullan, MBBS, Ph.D. We are currently recruiting for clinical trials on the following diseases. Alzheimer’s Disease […]
On January 25th, we announceed the discovery of a new class of drugs that lower the production of the main pathological protein that causes Alzheimer’s diseas. Our annoucement got picked up in the press. Following is a roundup of press mentions: Sarasota’s Roskamp Institute Discovers New Class Of Drugs That Can Impact Alzheimer’s Disease Medical […]